First Trust Direct Indexing L.P. - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.

Quarter-by-quarter ownership
First Trust Direct Indexing L.P. ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$410,161
+42.4%
11,371
+50.8%
0.05%
+35.3%
Q1 2023$288,000
-31.7%
7,541
+1.7%
0.03%
-39.3%
Q4 2022$421,743
+47.5%
7,412
+2.5%
0.06%
+33.3%
Q3 2022$286,000
-10.1%
7,2300.0%0.04%
-4.5%
Q2 2022$318,000
+7.4%
7,230
-2.7%
0.04%
+22.2%
Q1 2022$296,000
+13.0%
7,427
+14.0%
0.04%
+5.9%
Q4 2021$262,000
-0.4%
6,516
+0.6%
0.03%
-8.1%
Q3 2021$263,000
-23.3%
6,475
-14.2%
0.04%
-27.5%
Q2 2021$343,000
+63.3%
7,546
+50.0%
0.05%
-8.9%
Q1 2021$210,000
+4.0%
5,030
+6.5%
0.06%
+3.7%
Q4 2020$202,0004,7220.05%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders